The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association

2017/03/01 by Daniel E. Freedberg, Lawrence S. Kim, Yu-Xiao Yang +1 · 28 citations
Medicine · #Gastroesophageal reflux and treatments #Helicobacter pylori-related gastroenterology studies #Potassium and Related Disorders

paper · doi:10.1053/j.gastro.2017.01.031

Citations

• Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial
• The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos)

Cited by

• Proton Pump Inhibitors: Review of Emerging Concerns
• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
• Proton-pump inhibitor [wikipedia]
• Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. [europepmc]
• Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update. [europepmc]
• Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. [europepmc]
• The Role of Deprescribing in Older Adults with Chronic Kidney Disease. [europepmc]
• Cost-effective care in eosinophilic esophagitis. [europepmc]
• The risks of long-term use of proton pump inhibitors: a critical review. [europepmc]
• Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved. [europepmc]
• Proton pump inhibitor: The dual role in gastric cancer. [europepmc]
• Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. [europepmc]
• Problems Associated with Deprescribing of Proton Pump Inhibitors. [europepmc]
• Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats. [europepmc]
• Molecular pathways driving omeprazole nephrotoxicity. [europepmc]
• Protective Effects of Wheat Peptides against Ethanol-Induced Gastric Mucosal Lesions in Rats: Vasodilation and Anti-Inflammation. [europepmc]
• Omeprazole improves chemosensitivity of gastric cancer cells by m6A demethylase FTO-mediated activation of mTORC1 and DDIT3 up-regulation. [europepmc]
• Adverse Effects Associated with Proton Pump Inhibitor Use. [europepmc]
• Dietary and Lifestyle Factors Related to Gastroesophageal Reflux Disease: A Systematic Review. [europepmc]
• Association between obesity and risk of fracture, bone mineral density and bone quality in adults: A systematic review and meta-analysis. [europepmc]
• Polypharmacy and Malnutrition Management of Elderly Perioperative Patients with Cancer: A Systematic Review. [europepmc]
• Eosinophilic Esophagitis: A Review. [europepmc]
• ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. [europepmc]
• Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions. [europepmc]
• Proton Pump Inhibitors and Bone Health: An Update Narrative Review. [europepmc]
• Burden of gastroesophageal reflux disease in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of disease study 2019. [europepmc]
• Proton Pump Inhibitor Use and Risk of Serious Infections in Young Children. [europepmc]
• ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions. [europepmc]